ELVN
What one share of Enliven Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being.
Enliven Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.67 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.06 |
| Cash and investments | $12.22 |
| Book value | $12.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$33.40 | $0.20 | −$31.34 | — | −$69.53 |
| 2021 | — | −$2.37 | $0.00 | −$2.16 | — | −$1.63 |
| 2022 | — | −$12.05 | $0.20 | −$10.46 | — | −$21.52 |
| 2023 | — | −$2.01 | $0.00 | −$1.73 | — | $5.96 |
| 2024 | — | −$1.89 | $0.00 | −$1.56 | — | $6.33 |
| 2025 | — | −$1.83 | $0.00 | −$1.24 | — | $7.73 |